tbuckley/cabot-search huggingface dataset:
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Authors: R J Motzer, P Lyn, P Fischer, P Lianes, R L Ngo, C Cordon-Cardo, J P O'Brien
Journal: Journal of Clinical Oncology (1995)

PURPOSE The reduced cardiac toxicity of the dextro-(d-) stereoisomer of verapamil (dexverapamil; Knoll Pharmaceuticals, Whippany, NJ) warrants its study as a potential multidrug-resistance (MDR) reversal agent. PATIENTS AND METHODS Twenty-three patients with advanced renal cell carcinoma (RCC) were treated with vinblastine at a dose of 0.11 mg/kg intravenous (IV) bolus injection on days 1 and 2 every 21 days. Dexverapamil was added to subsequent cycles after resistance had been demonstrated. Dexverapamil treatment was begun 18 hours before day 1 of vinblastine administration and was given orally every 6 hours for 12 doses. Patients in group A were treated with a dose of 120 mg/m2, and those in group B were treated with 180 mg/m2 plus dexamethasone; plasma concentrations achieved in patients were correlated with in vitro effects. RESULTS Toxicities included hypotension, asymptomatic bradycardia, and mild atrioventricular conduction delays, although one patient had dexverapamil discontinued for grade IV congestive heart failure. There were no partial or complete responses. The mean day-1 serum dexverapamil plus norverapamil plasma concentrations were 2,575 ng/mL (range, 697 to 6,015 ng/mL) for group A and 1,654 ng/mL (range, 710 to 4,132 ng/mL) for group B at the time of vinblastine administration. These concentrations were in the range of those that reversed vinblastine resistance in vitro. CONCLUSION The advantage of dexverapamil as an MDR reversal agent is its potential for achieving desired blood levels with substantially less toxicity than the racemic mixture of verapamil. Based on tolerability, it is a suitable drug for further study in clinical trials of malignancies other than RCC that attempt to achieve MDR reversal. The dose of 120 mg/m2 given orally every 6 hours, with dose escalation based on individual tolerance, represents a feasible schedule to be considered for such studies.
Direct Relationship Between High-Energy Phosphate Content and Blood Flow in Thermally Treated Murine Tumors2
Authors: Michael B. Lilly, Charles R. Katholi, Thian C. Ng
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article Direct Relationship Between High-Energy Phosphate Content and Blood Flow in Thermally Treated Murine Tumors Get access Michael B. Lilly, Michael B. Lilly Search for other works by this author on: Oxford Academic PubMed Google Scholar Charles R. Katholi, Charles R. Katholi Search for other works by this author on: Oxford Academic PubMed Google Scholar Thian C. Ng Thian C. Ng Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 75, Issue 5, November 1985, Pages 885–889, https://doi.org/10.1093/jnci/75.5.885 Published: 01 November 1985 Article history Received: 05 October 1984 Revision received: 21 May 1985 Accepted: 17 July 1985 Published: 01 November 1985
Enhancement of DL-Ethionine-Induced Liver Carcinogenesis in Rats Fed a Choline-Devoid Diet&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Hisashi Shinozuka, Benito Lombardi, Stewart Sell, Richard M. Iammarino
Journal: JNCI Journal of the National Cancer Institute (1978)

The effects of a choline-devoid (CD) or a choline-supplemented (CS) diet on the induction of liver tumors in rats by dl-ethionine were investigated. Groups of male outbred Sprague-Dawley rats were fed a plain CD or a plain CS diet, or the same diets containing 0.05% dl-ethionine. Hepatocellular carcinomas developed in 50% of the rats fed the CD+ethionine diet for 14 weeks, and in about 80% of the rats fed the same diet for 22–30 weeks. No hepatocellular carcinomas developed in rats fed the CS+ethionine diet, the plain CD diet, or the plain CS diet up to 30 weeks. The findings suggest that a CD diet alters the response of rat liver to dl-ethionine and leads to an early and enhanced induction of hepatocellular carcinoma.
Making Devices Cyber Safe
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of &lt;italic&gt;Propionibacterium acnes&lt;/italic&gt; on the Cellular Immune Responses to Tumor-Specific Antigens on Malignant Rat Liver Cells
Authors: Yokota, T., Katahira, S., Konno, K., Minami, K.
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Effect of Propionibacterium acnes on the Cellular Immune Responses to Tumor-Specific Antigens on Malignant Rat Liver Cells Get access T. Yokota, T. Yokota 2Department of Bacteriology, Fukushima Medical College, Fukushima 960, Japan. Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Katahira, S. Katahira 2Department of Bacteriology, Fukushima Medical College, Fukushima 960, Japan. Search for other works by this author on: Oxford Academic PubMed Google Scholar K. Konno, K. Konno 2Department of Bacteriology, Fukushima Medical College, Fukushima 960, Japan. Search for other works by this author on: Oxford Academic PubMed Google Scholar K. Minami K. Minami 2Department of Bacteriology, Fukushima Medical College, Fukushima 960, Japan. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 62, Issue 6, June 1979, Pages 1511–1515, https://doi.org/10.1093/jnci/62.6.1511 Published: 01 June 1979 Article history Received: 18 July 1978 Accepted: 13 November 1978 Published: 01 June 1979
Phone clinic provides excellent support
Authors: M. Brada, N. D James
Journal: BMJ (1995)

regarded as part of the workload.Problems can arise with such a service.Patients may be unable to get through on the telephone.They may justifiably become irritated if kept waiting, especially if they are telephoning from a call box or abroad and incur unnecessary expense.A policy must be agreed for patients who fail to telephone for results.Finally, the sifting out of patients who are quick and easy to deal with means that only patients with more complicated problems attend for follow up, which increases the consultation time.Overall our patients appreciate the service.Most of them are young, fit, and in employment, and some are prepared to travel long distances to use the confidential service provided by a geni- tourinary medicine clinic.Reducing the number of visits to the clinic saves them time and money.Furthermore, if follow up by telephone was unavailable resources would have to be found to see these patients in the clinic.We think that more clinicians and patients could benefit from our experience.
PET Imaging of Tau Deposition in the Aging Human Brain
Authors: Michael Schöll, Samuel N. Lockhart, Daniel R. Schonhaut, James P. O’Neil, Mustafa Janabi, Rik Ossenkoppele, Suzanne L. Baker, Jacob W. Vogel, Jamie Faria, Henry D. Schwimmer, Gil D. Rabinovici, William J. Jagust
Journal: Neuron (2016)
Empowering Adult Stem Cells for Myocardial Regeneration V2.0
Authors: Kathleen M. Broughton, Mark A. Sussman
Journal: Circulation Research (2016)

Much has changed since our survey of the landscape for myocardial regeneration powered by adult stem cells 4 years ago. 1 The intervening years since that first review has witnessed an explosive expansion of studies that advance both understanding and implementation of adult stem cells in promoting myocardial repair. Painstaking research from innumerable laboratories throughout the world is prying open doors that may lead to restoration of myocardial structure and function in the wake of pathological injury. This global effort has produced deeper mechanistic comprehension coupled with an evolving appreciation for the complexity of myocardial regeneration in the adult context. Undaunted by both known and (as yet) unknown challenges, pursuit of myocardial regenerative medicine mediated by adult stem cell therapy has gathered momentum fueled by tantalizing clues and visionary goals. This concise review takes a somewhat different perspective than our initial treatise, taking stock of the business sector that has become an integral part of the field while concurrently updating state of affairs in cutting edge research. Looking retrospectively at advancement over the years as all reviews eventually must, the fundamental lesson to be learned is best explained by Jonatan Mårtensson: “Success will never be a big step in the future. Success is a small step taken just now.”
Detection of Circulating Mammary Carcinoma Cells in the Peripheral Blood of Breast Cancer Patients Via a Nested Reverse Transcriptase Polymerase Chain Reaction Assay for Mammaglobin mRNA
Authors: Otto Zach, Hedwig Kasparu, Otto Krieger, Wolfgang Hehenwarter, Michael Girschikofsky, Dieter Lutz
Journal: Journal of Clinical Oncology (1999)

According to current medical research, mammaglobin (hMAM) is expressed exclusively in the mammary glands of adult women and in mammary tumor cell lines. Therefore, we examined hMAM expression as a marker for the detection of carcinoma cells in the peripheral blood of patients with breast cancer (BC).Blood samples obtained from 114 BC patients at the various stages of their disease and from 68 individuals without BC were screened for hMAM mRNA by a nested reverse transcriptase polymerase chain reaction (RT-PCR) assay.The assay exhibited a calculated analytical limit of one tumor cell per 10(6) to 10(7) WBCs. None of the samples from peripheral blood of 27 healthy individuals were positive, whereas 29 (25%) of 114 samples from BC patients were positive for hMAM mRNA. hMAM mRNA expression was detected in five (28%) of 18 BC patients at diagnosis, in three (6%) of 53 with no evidence of disease, and in 21 (49%) of 43 with metastatic disease. These results correlate with patients' carcinoembryonic antigen (CEA) plasma level and, to some extent, with estrogen receptor status. Two of 41 samples from patients with malignancies other than BC were also positive.In contrast to healthy volunteers, hMAM transcripts were detected in the peripheral blood of BC patients. The percentage of positivity relates to the clinical stages of disease, CEA plasma level, and estrogen receptor status. Aberrant hMAM expression might occur occasionally in malignancies other than BC. The clinical relevance of hMAM RT-PCR-based tumor cell detection in the peripheral blood of BC patients should be further evaluated in prospective studies.
Three‐Dimensional Graphene: A Biocompatible and Biodegradable Scaffold with Enhanced Oxygenation
Authors: Manuela Loeblein, Guillaume Perry, Siu Hon Tsang, Wenjin Xiao, Dominique Collard, Philippe Coquet, Yasuyuki Sakai, Edwin Hang Tong Teo
Journal: Advanced Healthcare Materials (2016)

Owing to its high porosity, specific surface area and three‐dimensional structure, three‐dimensional graphene (3D–C) is a promising scaffold material for tissue engineering, regenerative medicine as well as providing a more biologically relevant platform for living organisms in vivo studies. Recently, its differentiation effects on cells growth and anti‐inflammation properties have also been demonstrated. Here, we report a complete study of 3D–C as a fully adequate scaffold for tissue engineering and systematically analyze its biocompatibility and biodegradation mechanism. The metabolic activities of liver cells (HepG2 hepatocarcinoma cells) on 3D‐C are studied and our findings show that cell growth on 3D–C has high cell viability (&gt; 90%), low lactate production (reduced by 300%) and its porous structure also provides an excellent oxygenation platform. 3D–C is also biodegradable via a 2‐step oxidative biodegradation process by first, disruption of domains and lift off of smaller graphitic particles from the surface of the 3D–C and subsequently, the decomposition of these graphitic flakes. In addition, the speed of the biodegradation can be tuned with pretreatment of O 2 plasma.
Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults
Authors: Crystal L. Mackall, Dagmar Stein, Thomas A. Fleisher, Margaret R. Brown, Frances T. Hakim, Catherine V. Bare, Susan F. Leitman, Elizabeth J. Read, Charles S. Carter, Leonard H. Wexler, Ronald E. Gress
Journal: Blood (2000)
Corrigendum re: “Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin” [Eur Urol 2016;69:197–200]
Authors: Ashish M. Kamat
Journal: European Urology (2016)
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
Authors: A Larocca, S Bringhen, M T Petrucci, S Oliva, A P Falcone, T Caravita, O Villani, G Benevolo, A M Liberati, F Morabito, V Montefusco, R Passera, L De Rosa, P Omedé, I D Vincelli, S Spada, A M Carella, E Ponticelli, D Derudas, M Genuardi, T Guglielmelli, C Nozzoli, E Aghemo, L De Paoli, C Conticello, C Musolino, M Offidani, M Boccadoro, P Sonneveld, A Palumbo
Journal: Leukemia (2016)
Presentation of Benefits and Harms in US Cancer Screening and Prevention Guidelines: Systematic Review
Authors: Tanner J. Caverly, Rodney A. Hayward, Elyse Reamer, Brian J. Zikmund-Fisher, Daniel Connochie, Michele Heisler, Angela Fagerlin
Journal: JNCI Journal of the National Cancer Institute (2016)

Cancer prevention and screening guidelines are ideally suited to the task of providing high-quality benefit-harm information that informs clinical practice. We systematically examined how US guidelines present benefits and harms for recommended cancer prevention and screening interventions. We included cancer screening and prevention recommendations from: 1) the United States Preventive Services Task Force, 2) the American Cancer Society, 3) the American College of Physicians, 4) the National Comprehensive Cancer Network, and 5) other US guidelines within the National Guidelines Clearinghouse. Searches took place November 20, 2013, and January 1, 2014, and updates were reviewed through July 1, 2015. Two coders used an abstraction form to code information about benefits and harms presented anywhere within a guideline document, including appendices. The primary outcome was each recommendation's benefit-harm "comparability" rating, based on how benefits and harms were presented. Recommendations presenting absolute effects for both benefits and harms received a "comparable" rating. Other recommendations received an incomplete rating or an asymmetric rating based on prespecified criteria. Fifty-five recommendations for using interventions to prevent or detect breast, prostate, colon, cervical, and lung cancer were identified among 32 guidelines. Thirty point nine percent (n = 17) received a comparable rating, 14.5% (n = 8) received an incomplete rating, and 54.5% (n = 30) received an asymmetric rating. Sixty-nine percent of cancer prevention and screening recommendation statements either did not quantify benefits and harms or presented them in an asymmetric manner. Improved presentation of benefits and harms in guidelines would better ensure that clinicians and patients have access to the information required for making informed decisions.
Initial therapy for chronic myelogenous leukemia: playing the odds.
Authors: S J Lee, C Anasetti, M M Horowitz, J H Antin
Journal: Journal of Clinical Oncology (1998)

For patients with newly diagnosed CML, the life expectancy is much better than it was 5 years ago. However, with improvements in both transplant and nontransplant therapy comes controversy over optimal first-line therapy. We argue that an evidence-based analysis that weighs the likelihoods of surviving transplantation and responding to interferon should help guide selection of initial therapy. Such a strategy would aggressively triage appropriate patients to curative therapy while advising those who are unlikely to do well with transplantation to elect less toxic therapy, which still confers a survival benefit. We realize that many other factors beside the ones mentioned here affect a clinician's recommendation for initial therapy and a patient's ultimate choice. Many extenuating circumstances, coexisting medical conditions, and personal values need to be a part of the ultimate decision. However, we hope that this guideline summarizes the current evidence and offers a rational approach to help guide newly diagnosed patients.
Caspase Activation Is Required for Nitric Oxide–Mediated, CD95(APO-1/Fas)–Dependent and Independent Apoptosis in Human Neoplastic Lymphoid Cells
Authors: Katerina Chlichlia, Marcus E. Peter, Marian Rocha, Carsten Scaffidi, Mariana Bucur, Peter H. Krammer, Volker Schirrmacher, Victor Umansky
Journal: Blood (1998)
Use of the National Death Index in Cancer Studies
Authors: B H Patterson, R Bilgrad
Journal: JNCI Journal of the National Cancer Institute (1986)

The National Death Index (NDI) is a central file of identifying information on all deaths occurring in the United States since 1979. Potential uses of the NDI as a tool for both short-term and long-term follow-up in cancer treatment, prevention, and occupational studies are suggested. The various steps involved in using the NDI and interpreting the results are described, along with factors influencing the effectiveness of the matching process.
Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.
Authors: Vikas Gupta, Maria R. Baer, Stephen T. Oh, Carole Brennan Miller, Susie Jun, Peter Lee, Hua Dong, Andreas Reiter
Journal: Journal of Clinical Oncology (2015)

TPS7102 Background: Momelotinib (MMB) is a JAK1/2 inhibitor, and displays potent in vitro inhibitory activity against cells dependent on JAK2 including cells with the JAK2V617F mutation. Dosing of ruxolitinib (RUX), the first JAK inhibitor approved for myelofibrosis (MF), is based on platelet count, with dose reduction indicated for various degrees of hematologic toxicity. In the phase III study of RUX versus placebo (PBO) in MF (COMFORT-1), 70% of subjects in the RUX arm experienced thrombocytopenia of any grade compared to 31% of subjects in the PBO arm, with rates of Grade 3 and 4 thrombocytopenia of 13% and 1% on the RUX and PBO arms, respectively. Grade 3 and 4 anemia rates were 45% and 19% for the RUX and PBO arms, respectively (Verstovsek et al, NEJM 2012). For those patients who experience significant hematologic toxicities while on RUX, no approved alternative JAK inhibitor therapy is currently available. Methods: 150 subjects with primary, post-polycythemia vera, or post-essential thrombocythemia MF will be randomized in a 2:1 manner to receive either MMB or best available therapy (BAT) for 24 weeks, with the option for eligible subjects to continue open-label MMB in an extended treatment phase for up to an additional 168 weeks. Treatment on the BAT arm may include RUX. Key inclusion criteria are palpable splenomegaly ≥ 5 cm, currently or previously treated with RUX and characterized by either requirement for red blood cell transfusion while on RUX, or dose adjustment of RUX to < 20 mg twice daily at start of or during RUX treatment plus either ≥ Grade 3 thrombocytopenia, ≥ Grade 3 anemia, and/or ≥ Grade 3 hemorrhage. The primary endpoint is Splenic Response Rate at Week 24, defined as the proportion of subjects who achieve ≥ 35% reduction in spleen volume from baseline at Week 24, as measured by MRI or CT scan. Secondary endpoints include Response Rate in Total Symptom Score, defined as the proportion of subjects who achieve ≥ 50% reduction in total symptom score from baseline to Week 24 as measured by the modified MPNSAF TSS diary. The DMC last reviewed the trial in Nov 2014 and recommended that the trial continue as planned. Clinical trial registry number: NCT02101268. Clinical trial information: NCT02101268.
Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.
Authors: L. Vamvakas, S. Agelaki, N. K. Kentepozidis, A. Karampeazis, A. G. Pallis, C. Christophyllakis, A. P. Kotsakis, I. Boukovinas, D. Mavroudis, V. Georgoulias
Journal: Journal of Clinical Oncology (2010)

7519 Background: To compare the efficacy of MTA and ERL as second-line treatment of patients with advanced/metastatic NSCLC. Methods: Pts were randomized either to MTA (500 mg/m2 on d1, every 3 weeks) or ERL (150 mg/d p.o.). Treatment could be third line for patients who did not received first-line platinum-based doublets. After the 7/2008 (Scagliotti G et al: JCO, 26: 3543,2008) only patients with adenocarcinomas were randomized. Primary endpoint was time to tumor progression (TTP). Results: From 1/2006-12/2009, 327pts were enrolled and the current analysis concerns 297 pts randomized to MTA (n = 147) or ERL (n = 150), which were already evaluable (29 pts too early). The clinicopathologic patients' characteristics were well balanced in the 2 arms. 24.5% and 24% pts with a squamous cell carcinoma were enrolled in the MTA and ERL arms, respectively; in 39% and 49% pts in the MTA and ERL arm, respectively treatment was third line (p = 0.067). There was no difference in terms of objective response rate (11.6% vs 6.8%; p = 0.166), median TTP (2.9 vs 3.6 months; p = 0.434) and median OS (8.9 vs 7.7 months; p = 0.528) between the MTA and ERL arms, respectively. The DCR was 34.1% in the MTA and 24.7% in the ERL arm (0.082). The incidence of recurrences was significantly higher in the ERL (91.3%) than in the MTA (78.9%) arm (p = 0.003). There was more grade 3-4 hematologic (neutropenia and thrombocytopenia) toxicity in the MTA arm and skin rash in the ERL arm. Conclusions: MTA and ERL have a good toxicity profile and demonstrated a comparable efficacy as salvage treatment in patients with advanced NSCLC. Subgroup analyses according to histology, line of treatment and EGFR mutation status will be presented. No significant financial relationships to disclose.